304859-15-2

Basic information

• Product Name: 5-OXO-1-(4-PYRIDINYLMETHYL)-3-PYRROLIDINECARBOXYLIC ACID
• Synonyms: UKRORGSYN-BB BBR-027809;3-pyrrolidinecarboxylic acid, 5-oxo-1-(4-pyridinylmethyl)-;5-oxo-1-(pyridin-4-ylmethyl)pyrrolidine-3-carboxylic acid(SALTDATA: FREE);5-keto-1-(4-pyridylmethyl)pyrrolidine-3-carboxylic acid;5-oxo-1-(4-pyridylmethyl)-3-pyrrolidinecarboxylic acid;5-oxo-1-(4-pyridylmethyl)pyrrolidine-3-carboxylic acid;CHEMBRDG-BB 4010216;ASISCHEM A63073
• CAS NO: 304859-15-2
• Molecular Formula: C₁₁H₁₂N₂O₃
• Molecular Weight: 220.22
• Mol File: 304859-15-2.mol

Chemical Properties

• Boiling Point: 515.3°C at 760 mmHg
• Flash Point: 265.4°C
• Appearance: /
• Density: 1.375g/cm³
• Vapor Pressure: 1.92E-11mmHg at 25°C
• Refractive Index: 1.61
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-OXO-1-(4-PYRIDINYLMETHYL)-3-PYRROLIDINECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-OXO-1-(4-PYRIDINYLMETHYL)-3-PYRROLIDINECARBOXYLIC ACID(304859-15-2)
• EPA Substance Registry System: 5-OXO-1-(4-PYRIDINYLMETHYL)-3-PYRROLIDINECARBOXYLIC ACID(304859-15-2)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 304859-15-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-OXO-1-(4-PYRIDINYLMETHYL)-3-PYRROLIDINECARBOXYLIC ACID is used as a potential active pharmaceutical ingredient for its unique structural features, which may contribute to the development of new drugs targeting specific medical conditions.
Used in Chemical Research:
In the field of chemical research, 5-OXO-1-(4-PYRIDINYLMETHYL)-3-PYRROLIDINECARBOXYLIC ACID serves as a subject of study for understanding its reactivity and exploring its potential as a building block in the synthesis of other complex organic compounds.
Used in Industrial Applications:
5-OXO-1-(4-PYRIDINYLMETHYL)-3-PYRROLIDINECARBOXYLIC ACID's high reactivity and unique structure make it a candidate for use in various industrial applications, potentially including the development of new materials, catalysts, or as an intermediate in the synthesis of other valuable chemicals.

InChI:InChI=1/C11H12N2O3/c14-10-5-9(11(15)16)7-13(10)6-8-1-3-12-4-2-8/h1-4,9H,5-7H2,(H,15,16)

Upstream product

• 3731-53-1 4-(aminomethyl)pyridine 
• 97-65-4 2-methylenesuccinic acid 

Relevant articles and documents

CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives

A novel lead compound, N-{3-[4-(4-fluorobenzoyl)piperidin-1-yl]propyl}-1- methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (1), was identified as a CCR5 antagonist by high-throughput screening using [125I]RANTES and CCR5-expressing CHO cells. The IC50 value of 1 was 1.9 μM. In an effort to improve the binding affinity of 1, a series of 5-oxopyrrolidine-3- carboxamides was synthesized. Introduction of 3,4-dichloro substituents to the central phenyl ring (10i, IC50=0.057 μM; 11b, IC 50=0.050 μM) or replacing the 1-methyl group of the 5-oxopyrrolidine moiety with a 1-benzyl group (12e, IC50=0.038 μM) was found to be effective for improving CCR5 affinity. Compound 10i, 11b, and 12e also inhibited CCR5-using HIV-1 envelope-mediated membrane fusion with IC50 values of 0.44, 0.19, and 0.49 μM, respectively.

CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF

A compound of the formula: wherein R1 is a hydrocarbon group, R2 is a hydrocarbon group having 2 or more carbon atoms, where R1 and R2 may in combination form, together with an adjacent nitrogen atom, a ring optionally having a substituent or substituents, R3 is a hydrocarbon group optionally having a substituent or substituents or a heterocyclic group optionally having a substituent or substituents, R4 is a hydrogen atom, a hydrocarbon group, a heterocyclic group and the like, E is a divalent chain hydrocarbon group and the like, G is CO or SO2, J is a nitrogen atom, a methine group and the like, and Q and R are each a divalent chain C1-3 hydrocarbon group and the like, and a salt thereof show a superior CCR5 antagonistic activity and are useful as agents for the prophylaxis or treatment of HIV infection of human peripheral blood mononuclear cells, particularly AIDS.